Comparative Effectiveness of Rituximab and Traditional Treatments for Multiple Sclerosis

Overview of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disorder that impacts the central nervous system. The symptoms experienced by patients can vary widely based on the regions of the brain affected, leading to issues such as vision problems, bladder dysfunction, mobility challenges, and sexual dysfunction. Unfortunately, these symptoms tend to worsen over time. In recent years, the landscape of drug therapy for MS has evolved, introducing new disease-modifying therapies. Nevertheless, traditional treatment options often face high rates of discontinuation.

Rituximab: An Off-Label Treatment

Originally approved for rheumatoid arthritis, rituximab has recently found off-label application for MS treatment in Sweden. Researchers at the Karolinska Institutet’s Department of Clinical Neuroscience in Stockholm seized the opportunity to perform a real-world effectiveness study comparing rituximab to traditional treatment options for MS. Their findings were published in the Journal of the American Medical Association Neurology.

Study Details

Patient Population

The Swedish multiple sclerosis registry provided data on 14,500 patients with MS, of which 494 newly diagnosed individuals participated in the study. These patients were treated with either rituximab, traditional injectable disease-modifying therapies, dimethyl fumarate, fingolimod, or natalizumab.

Study Design and Outcomes

The observational nature of the study meant that baseline characteristics varied among patients receiving different therapies. The primary outcome assessed was the discontinuation of the prescribed medication, along with reasons for therapy cessation. Secondary outcomes included side effects, the presence of brain lesions on MRI scans, and relapse rates.

Findings: Rituximab vs. Traditional Treatments

Discontinuation Rates

The study revealed that patients receiving rituximab had a significantly higher continuation rate compared to those on traditional therapies. Discontinuation among patients on injectable disease-modifying therapies, dimethyl fumarate, and fingolimod was more frequently attributed to disease relapse or side effects. In contrast, patients on rituximab primarily discontinued treatment due to pregnancy, with only 0.8% stopping because of disease progression. Notably, positive JC virus blood results were the leading reason for discontinuation among natalizumab recipients.

Relapse Rates and Brain Lesions

Rituximab was associated with lower relapse rates compared to traditional injectable therapies. However, no significant differences were found in relapse rates when comparing rituximab to dimethyl fumarate or fingolimod. Additionally, rituximab resulted in fewer brain lesions compared to injectable disease-modifying therapies and dimethyl fumarate.

Side Effect Profile

The side effect profiles of the treatment groups were largely similar, with no significant differences noted between rituximab, fingolimod, and natalizumab. While injectable disease-modifying therapies exhibited more mild side effects, the incidence of moderate to severe side effects was comparable across all treatment groups.

Conclusion

This observational study indicates that rituximab, despite being an off-label option for MS, demonstrates a lower discontinuation and relapse rate compared to traditional treatment options. Further research with a larger cohort is necessary to validate the effectiveness and safety of rituximab for patients with multiple sclerosis.

References

(1) Granqvist M, Boremalm M, Poorghobad A, et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurol. 2018
(2) Hillert J, Stawiarz L. The Swedish MS registry – clinical support tool and scientific resource. Acta Neurol Scand. 2015.